IMR Press / FBL / Volume 5 / Issue 3 / DOI: 10.2741/petkova

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Article
Cell cycle molecules and diseases of the cardiovascular system
Show Less
1 Department of Pathology, Division of Tropical Medicine and Parasitology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York 10461, USA
2 Department of Medicine Divisions of Infectious Diseases, Cardiology and Endocrinology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York 10461, USA
3 The Albert Einstein Cancer Center, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York 10461, USA
Front. Biosci. (Landmark Ed) 2000, 5(3), 452–460; https://doi.org/10.2741/petkova
Published: 1 April 2000
Abstract

Injury to the cardiovascular system causes an elevated expression of endothelin-1 (ET-1) and activation of several important signaling pathways including the mitogen-activated kinase (MAPK) cascade. The activation of these pathways has been implicated in the pathogenesis of cardiovascular disease caused by hypoxia, infections, and ischemia /reperfusion injury, cardiomyopathy and restenosis after balloon angioplasty. Important downstream targets of the MAPK and ET-1 pathways are the cell cycle regulatory molecules (cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors). Regulation of these molecules contributes to remodeling throughout the cardiovascular system. In addition, cell cycle molecules are important in the regulation of angiogenesis. These new data have led to the development of potential therapeutic modalities targeting these regulatory molecules in order to ameliorate various cardiovascular disease states.

Keywords
Cardiovascular system
MAPK
Endothelin
Cell cycle
Trypanosoma cruzi
Review
Share
Back to top